Multiple Myeloma
Conference Coverage
Ruxolitinib overcame lenalidomide resistence in myeloma
The clinical trial is the first to demonstrate the activity of a JAK inhibitor in the treatment of myeloma patients.
News
CAR T therapy to enter early testing in multiple myeloma
The phase 1b/2 trial will begin enrollment in the second half of 2018.
News
More evidence links increased BMI to higher multiple myeloma risk
MM risk rose almost 30% for every 5 kg/m2 increase in young adult BMI.
News
In myeloma, third ASCT is a viable option
The analysis identifies relapse-free interval as a prognostic factor.
Best Practices
Treatment and Management of Multiple Myeloma
A panel discussion of the challenges and standards of care for managing patients with multiple myeloma.
News
Meningococcal Arthritis Masking as Possible Myeloma
Clinicians reveal the importance of screening for an underlying impaired immune response when patients present with rare symptoms.
News
Continue to opt for HDT/ASCT for multiple myeloma
A systematic review and meta-analysis confirms that HDT/ASCT is still the best option for newly-diagnosed multiple myeloma.
News
Anti-BCMA CAR T-cell therapy being fast tracked at FDA
The CAR T-cell therapy bb2121 was granted breakthrough therapy designation by the Food and Drug Administration, speeding its review process.
Conference Coverage
Late-breaking abstracts highlight treatment advances in CLL, myeloma, and more
ASH President Kenneth C. Anderson, MD, and ASH Secretary Robert A. Brodsky, MD, gave a preview of four practice-changing studies.
News
Cyclophosphamide after transplant reduced GVHD in myeloma patients
Anticancer agents may be more active after transplantation than before, researchers suggested.
